The risk of cancer in patients suffering from diabetes increases if they are using glargine, an insulin analogue. 

A new study was done by a collaboration of the Institute for Quality and Efficiency in Health Care (IQWiG) and a research institute of the German Local Health Care Fund on about 130, 000 patients who had diabetes. These patients were using insulin or glargine, aspart or lispro (insulin analogues). The study was conducted between 2001 January and 2005 June. 

In their study, the researchers found out that malignancies were more frequent in diabetes patients who were prescribed glargine than when compared with those who were using human insulin. They also added that even though they did not possess the absolute evidences with regard to this factor, urgent suspicion has led to providing treatments for such patients. 

The researchers also have revealed that no differences were found in patients who were prescribed insulin analogues lispro and aspart, as well as human insulin. The authors of this study also added that the dose dependant relation with glargine confirms the doubt that this insulin analogue plays a vital role in diabetes patients developing cancer.

But they also mentioned that since the study has not been proved completely, those who are using glargine need not rush to change their drug.